Allergy care platform Nectar raised $16.5 million in a Series A round led by Harmony Partners, with participation from founding partners Juxtapose and Obvious Ventures, who co-built the company with founding CEO Kenneth Chahine, Ph.D.
Nectar’s latest fundraising round, which builds on their March 2022 seed investment and brings total equity raised to over $24M, will allow the company to invest in three key areas in 2023: scaling its virtual care platform nationwide, launching its first physical location to comprehensively treat allergies, and initiating clinical studies. Nectar is the consumer-facing brand of Nectar Life Sciences, an allergy-focused healthcare holding company led by Dr. Chahine. Read more.
